Novo Nordisk reports positive data from Victoza analyses

Novo Nordisk has reported data from new studies that provide further evidence of the benefits of Victoza, its liraglutide-based therapy for type 2 diabetes.

Recent analyses have shown that the drug is able to deliver better rates of blood glucose reduction after 26 weeks of treatment than a pair of alternative therapy options.

A further study demonstrated that Victoza can also provide advantages when used as an add-on to metformin, thus helping patients to reduce their risk of complications associated with the disease.

The drug has been approved for use in Europe since 2009 and has been prescribed to more than half a million patients worldwide to date.

Dr Allen King from the Diabetes Care Centre in Salinas said: "We know that by achieving treatment goals sooner, outcomes are improved so it's important that effective treatments, such as liraglutide, are used early in the management of type 2 diabetes."

Last month, the company applied for European and US regulatory approval of turoctocog alfa, a new compound for use in the treatment of haemophilia A.